Healthcare provider profile · identity verified

Mark P Snell, D.O.

Allopathic & Osteopathic Physicians|Family Medicine · CLINTON, MO · NPI 1427025600

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Mark P Snell, D.O. received $78.50 in general payments during 2025 across 5 reported records.

Otsuka America Pharmaceutical, Inc. accounted for 79.8% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 361 claims for Jardiance by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$78.50

5 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Otsuka America Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$62.64	79.8%	4	2025
Boehringer Ingelheim Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$15.86	20.2%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$78.50	5

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
REXULTI Normalized: rexulti	Drug	Otsuka America Pharmaceutical, Inc.	$62.64	4	2025
Source payment records 2025-01-27 · Otsuka America Pharmaceutical, Inc. · $15.90 · Open Payments source 2025-03-31 · Otsuka America Pharmaceutical, Inc. · $14.46 · Open Payments source 2025-06-16 · Otsuka America Pharmaceutical, Inc. · $15.61 · Open Payments source 2025-10-27 · Otsuka America Pharmaceutical, Inc. · $16.67 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583	Jardiance · 2024 Exact normalized brand match · 1 Part D row	361	46

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	935	122
Losartan Potassium	Losartan Potassium	588	94
Atorvastatin Calcium	Atorvastatin Calcium	569	104
Amlodipine Besylate	Amlodipine Besylate	551	99
Potassium Chloride	Potassium Chloride	487	61
Pravastatin Sodium	Pravastatin Sodium	468	83
Lisinopril	Lisinopril	458	94
Gabapentin	Gabapentin	422	47
Furosemide	Furosemide	415	72
Jardiance	Empagliflozin	361	46
Tramadol Hcl	Tramadol Hcl	351	73
Tamsulosin Hcl	Tamsulosin Hcl	337	49
Meloxicam	Meloxicam	324	76
Metoprolol Succinate	Metoprolol Succinate	303	56
Buspirone Hcl	Buspirone Hcl	279	39
Eliquis	Apixaban	279	34
Sertraline Hcl	Sertraline Hcl	270	35
Donepezil Hcl	Donepezil Hcl	232	34
Omeprazole	Omeprazole	231	51
Famotidine	Famotidine	228	39
Metformin Hcl	Metformin Hcl	227	48
Metoprolol Tartrate	Metoprolol Tartrate	227	36
Lovastatin	Lovastatin	221	52
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	213	65
Lorazepam	Lorazepam	213	33
Ropinirole Hcl	Ropinirole Hcl	211	30
Pantoprazole Sodium	Pantoprazole Sodium	206	44
Hydrochlorothiazide	Hydrochlorothiazide	197	41
Trazodone Hcl	Trazodone Hcl	194	29
Duloxetine Hcl	Duloxetine Hcl	189	25
Carvedilol	Carvedilol	180	30
Metformin Hcl Er	Metformin Hcl	170	40
Allopurinol	Allopurinol	167	23
Quetiapine Fumarate	Quetiapine Fumarate	164	19
Ezetimibe	Ezetimibe	160	47
Citalopram Hbr	Citalopram Hydrobromide	152	29
Rosuvastatin Calcium	Rosuvastatin Calcium	149	33
Alendronate Sodium	Alendronate Sodium	148	35
Trulicity	Dulaglutide	137	17
Simvastatin	Simvastatin	135	30
Spironolactone	Spironolactone	132	28
Albuterol Sulfate Hfa	Albuterol Sulfate	131	47
Fluoxetine Hcl	Fluoxetine Hcl	129	19
Memantine Hcl	Memantine Hcl	124	12
Mirtazapine	Mirtazapine	124	22
Clonazepam	Clonazepam	123	33
Escitalopram Oxalate	Escitalopram Oxalate	118	18
Xarelto	Rivaroxaban	115	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	104	18
Clopidogrel	Clopidogrel Bisulfate	102	24
Benazepril Hcl	Benazepril Hcl	98	15
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	92	suppressed
Atenolol	Atenolol	89	17
Primidone	Primidone	86	suppressed
Torsemide	Torsemide	85	20
Myrbetriq	Mirabegron	82	suppressed
Montelukast Sodium	Montelukast Sodium	80	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	78	19
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	77	32
Finasteride	Finasteride	75	11
Fluticasone Propionate	Fluticasone Propionate	75	18
Carbidopa-Levodopa	Carbidopa/Levodopa	74	suppressed
Pregabalin	Pregabalin	71	19
Warfarin Sodium	Warfarin Sodium	71	suppressed
Cephalexin	Cephalexin	68	54
Fluvoxamine Maleate	Fluvoxamine Maleate	65	suppressed
Ibuprofen	Ibuprofen	63	15
Risperidone	Risperidone	62	suppressed
Lamotrigine	Lamotrigine	61	suppressed
Valsartan	Valsartan	60	suppressed
Amiodarone Hcl	Amiodarone Hcl	57	12
Divalproex Sodium	Divalproex Sodium	56	suppressed
Diazepam	Diazepam	55	12
Olanzapine	Olanzapine	53	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	53	suppressed
Baclofen	Baclofen	51	suppressed
Alprazolam	Alprazolam	50	13
Fentanyl	Fentanyl	50	15
Celecoxib	Celecoxib	48	suppressed
Estradiol	Estradiol	48	suppressed
Levetiracetam	Levetiracetam	48	suppressed
Nystatin	Nystatin	48	26
Bupropion Xl	Bupropion Hcl	47	suppressed
Azithromycin	Azithromycin	46	39
Phenobarbital	Phenobarbital	46	suppressed
Farxiga	Dapagliflozin Propanediol	45	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	43	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	43	suppressed
Ondansetron Hcl	Ondansetron Hcl	42	21
Oxycodone Hcl	Oxycodone Hcl	42	suppressed
Austedo Xr	Deutetrabenazine	41	suppressed
Glimepiride	Glimepiride	41	11
Hydroxyzine Hcl	Hydroxyzine Hcl	41	suppressed
Sucralfate	Sucralfate	40	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	39	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	38	suppressed
Temazepam	Temazepam	37	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	36	suppressed
Aripiprazole	Aripiprazole	36	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	36	20
Risedronate Sodium	Risedronate Sodium	36	suppressed
Carbamazepine	Carbamazepine	35	suppressed
Lacosamide	Lacosamide	35	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	34	suppressed
Hydralazine Hcl	Hydralazine Hcl	34	suppressed
Tizanidine Hcl	Tizanidine Hcl	34	11
Albuterol Sulfate	Albuterol Sulfate	32	20
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	32	11
Ozempic	Semaglutide	32	suppressed
Carbamazepine Er	Carbamazepine	31	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	31	suppressed
Acyclovir	Acyclovir	30	15
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	30	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	30	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	30	19
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	29	suppressed
Irbesartan	Irbesartan	28	suppressed
Fluconazole	Fluconazole	27	17
Insulin Lispro Kwikpen U-100	Insulin Lispro	27	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	27	suppressed
Azelastine Hcl	Azelastine Hcl	26	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	26	suppressed
Bupropion Hcl Sr	Bupropion Hcl	26	suppressed
Desmopressin Acetate	Desmopressin Acetate	26	suppressed
Entresto	Sacubitril/Valsartan	26	suppressed
Ramipril	Ramipril	26	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	25	21
Xcopri	Cenobamate	25	suppressed
Nystop	Nystatin	24	15
Trintellix	Vortioxetine Hydrobromide	24	suppressed
Zonisamide	Zonisamide	24	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	23	suppressed
Memantine Hcl Er	Memantine Hcl	23	suppressed
Nitroglycerin	Nitroglycerin	23	19
Medroxyprogesterone Acetate	Medroxyprogesterone Acetate	22	suppressed
Breo Ellipta	Fluticasone/Vilanterol	21	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	21	suppressed
Tradjenta	Linagliptin	21	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	20	suppressed
Meclizine Hcl	Meclizine Hcl	20	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	20	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	19	18
Ciprofloxacin Hcl	Ciprofloxacin Hcl	19	14
Enoxaparin Sodium	Enoxaparin Sodium	19	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	19	suppressed
Synthroid	Levothyroxine Sodium	19	suppressed
Timolol Maleate	Timolol Maleate	19	suppressed
Verapamil Er	Verapamil Hcl	19	suppressed
Bumetanide	Bumetanide	18	suppressed
Diclofenac Sodium	Diclofenac Sodium	18	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	18	suppressed
Methotrexate	Methotrexate Sodium	18	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	17	17
Ceftriaxone	Ceftriaxone Sodium	17	14
Colestipol Hcl	Colestipol Hcl	17	suppressed
Mounjaro	Tirzepatide	17	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	17	17
Prednisone	Prednisone	17	suppressed
Austedo	Deutetrabenazine	16	suppressed
Diltiazem Hcl	Diltiazem Hcl	16	suppressed
Levemir Flexpen	Insulin Detemir	16	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	16	suppressed
Anastrozole	Anastrozole	15	suppressed
Enalapril Maleate	Enalapril Maleate	15	suppressed
Levofloxacin	Levofloxacin	15	13
Methylprednisolone	Methylprednisolone	15	15
Risperdal Consta	Risperidone Microspheres	15	suppressed
Rybelsus	Semaglutide	15	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Budesonide	Budesonide	14	suppressed
Cholestyramine	Cholestyramine (With Sugar)	14	suppressed
Digoxin	Digoxin	14	suppressed
Enulose	Lactulose	14	suppressed
Incruse Ellipta	Umeclidinium Bromide	14	suppressed
Paroxetine Hcl	Paroxetine Hcl	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Amoxicillin	Amoxicillin	13	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	13	suppressed
Divalproex Sodium Er	Divalproex Sodium	13	suppressed
Nabumetone	Nabumetone	13	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	13	suppressed
Nifedipine Er	Nifedipine	13	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	13	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	13	suppressed
Repatha Sureclick	Evolocumab	13	suppressed
Bicalutamide	Bicalutamide	12	suppressed
Januvia	Sitagliptin Phosphate	12	suppressed
Lurasidone Hcl	Lurasidone Hcl	12	suppressed
Methocarbamol	Methocarbamol	12	suppressed
Progesterone	Progesterone, Micronized	12	suppressed
Symbicort	Budesonide/Formoterol Fumarate	12	suppressed
Tiagabine Hcl	Tiagabine Hcl	12	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	11	suppressed
Fluocinolone Acetonide Oil	Fluocinolone Acetonide Oil	11	suppressed
Fluphenazine Hcl	Fluphenazine Hcl	11	suppressed
Galantamine Hbr	Galantamine Hbr	11	suppressed
Lidocaine	Lidocaine	11	suppressed
Phenytoin	Phenytoin	11	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	11	suppressed
Silver Sulfadiazine	Silver Sulfadiazine	11	suppressed
Tresiba Flextouch U-100	Insulin Degludec	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$78.50 · 5 records	Otsuka America Pharmaceutical, Inc.	REXULTI	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error